Imetelstat specifically binds to the RNA template of telomerase, effectively blocking its activity. By inhibiting telomerase, imetelstat leads to progressive telomere shortening, which eventually results in cancer cell death or senescence. This mechanism is particularly advantageous in treating cancers with high telomerase activity, such as certain hematological malignancies and solid tumors.
